MIV Therapeutics' Advanced Stent Coating Technologies Praised in Respected Germany-Based Investment Newsletter; Article Targeted to European Financial Community Features MIVT's Innovative Development Program.

VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new-generation biocompatible coatings and advanced drug delivery systems, has announced that the Company was the subject of an article in a recent issue of "Der Aktionar," an investment and finance periodical published in Germany, which praised the medical and marketplace potential of the Company's innovative drug-eluting stent technologies as well as its novel stroke-preventing devices.

The "Der Aktionar" article, "MIV Therapeutics - Forward-Looking Technology," praises the Company's pioneering proprietary technology program for the improvement of coronary stent safety and biocompatibility, as well as its other notable contributions to the field of stroke prevention.

The article concludes, "Investors should take advantage of the present consolidation phase of MIV Therapeutics and put a few shares in their security accounts. While it is true that the company is still in the development stage with this technology, the preclinical tests have already been unfolding with great success. If MIV continues the successful course it has enjoyed up to now, the market launch of this technology will likely only be a matter of time."

The article in "Der Aktionar" was published originally in German. Interested investors can read an English language translation of the article at http://www.trilogy-capital.com/tcp/mivt/article.html. (The article can be viewed in the original German at http://www.deraktionaer.de/xist4c/web/MIV-Therapeutics--- Zukunftsweisende-Technologie_id_2092__dId_5277999_.htm.) (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

As part of its comprehensive development program, MIVT develops a wide range of biocompatible medical device coating technologies based on its proprietary Hydroxyapatite (HAp) technology, a natural substance found in human bone and teeth that has thus far demonstrated excellent biocompatibility and safety particularly compared to leading polymer-based coatings on the market. MIVT is developing its coating systems to target the estimated $6 billion worldwide stent market. Some biomedical industry analysts predict that the global market for drug-eluting stents and other drug-delivery applications will grow to $100 billion or more in coming years.

In addition, MIVT's SagaX subsidiary is developing a novel implantable device, the Aortic Embolic Protection Device, designed to prevent stroke by filtering out embolic particles and blood clots that could otherwise migrate to the brain and trigger the blockages that cause strokes. Stroke is the third leading cause of death and the leading cause of severe disability in the world.

About MIV Therapeutics

MIV Therapeutics is developing a next generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. MIVT's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction of metal stents. MIVT's ultra-thin coating has been derived from a unique biocompatible material called Hydroxyapatite (HAp) that demonstrated during in-vivo animal trials excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and received a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council - Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.